Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Amarin Corp. pl, Eddingpharm deal

    Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Eddingpharm Inc., Shanghai, China Business: Cardiovascular Amarin granted Eddingpharm exclusive rights to develop and commercialize Vascepa icosapent ethyl in China, …

    Published on 3/2/2015
  • BioNovion, Genmab deal

    BioNovion B.V., Oss, the Netherlands Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Business: Antibodies Genmab partnered with BioNovion to co-develop and co-commercialize bispecific antibodies targeting immune …

    Published on 3/2/2015
  • Covance Inc, LabCorp deal

    Covance Inc. (NYSE:CVD), Princeton, N.J. Laboratory Corp. of America Holdings (NYSE:LH), Burlington, N.C. Business: Diagnostic LabCorp completed its acquisition of Covance for $107.19 per share. For each share held, …

    Published on 3/2/2015
  • Diagnoplex, Novigenix deal

    Diagnoplex S.A., Epalinges, Switzerland Novigenix S.A., Epalinges, Switzerland Business: Cancer Novigenix purchased Diagnoplexs Colox, which is approved in Europe to detect colorectal cancer and pre-cancerous lesions …

    Published on 3/2/2015
  • Dilaforette, Ergomed deal

    Dilaforette AB, Solna, Sweden Ergomed plc (LSE:ERGO), Guilford, U.K. Business: Hematology Dilaforette will pay Ergomed an undisclosed sum to conduct an international Phase II trial of Dilaforettes sevuparin to treat …

    Published on 3/2/2015
  • Flexus Biosciences, Bristol-Myers deal

    Flexus Biosciences Inc., San Carlos, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Bristol-Myers will acquire Flexus for $800 million up front and up to $450 million in development …

    Published on 3/2/2015
  • Genomic Vision S.A, Quest Diagnostics deal

    Genomic Vision S.A. (Euronext:GV), Paris, France Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Diagnostic The companies amended and extended to November 2018 a November 2010 contract granting Quest …

    Published on 3/2/2015
  • Georgia State University, Cisen Pharmaceutical deal

    Georgia State University, Atlanta, Ga. Cisen Pharmaceutical Co. Ltd., Jining, China Business: Cancer Cisen and Georgia State partnered to develop a preclinical compound from the university to treat leukemia in China. …

    Published on 3/2/2015
  • Heptares, Sosei deal

    Heptares Therapeutics Ltd., Welwyn Garden City, U.K. Sosei Group Corp. (Tokyo:4565), Tokyo, Japan Business: Neurology Sosei acquired Heptares for $180 million in cash and up to $220 million in regulatory milestones. …

    Published on 3/2/2015
  • Hyperion Therapeutics Inc, Clal, Weizmann Institute of Science deal

    Hyperion Therapeutics Inc. (NASDAQ:HPTX), South San Francisco, Calif. Clal Biotechnology Industries Ltd. (Tel Aviv:CBI), Tel Aviv, Israel Weizmann Institute of Science, Rehovot, Israel Business: Endocrine/Metabolic …

    Published on 3/2/2015
  • Immune Targeting Systems, Vaxin deal

    Immune Targeting Systems Ltd., London, U.K. Vaxin Inc., Rockville, Md. Business: Infectious, Cancer Vaxin is acquiring fellow vaccine company Immune for an undisclosed sum. Vaxin will gain an HBV vaccine, which is …

    Published on 3/2/2015
  • Isis Pharmaceuticals Inc, Biogen Idec deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Biogen Idec Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Neurology Isis received a $10 million milestone payment from Biogen under a 2013 deal under which the …

    Published on 3/2/2015
  • Merck & Co. Inc, Medicines Patent Pool deal

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Medicines Patent Pool, Geneva, Switzerland Business: Infectious Merck granted the Medicines Patent Pools a non-exclusive license to pediatric formulations of …

    Published on 3/2/2015
  • Meritage, Shire deal

    Meritage Pharma Inc., San Diego, Calif. Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Inflammation Shire exercised its option to acquire Meritage for $70 million in cash up front, plus up to $175 million in…

    Published on 3/2/2015
  • NGM Biopharmaceuticals, Merck deal

    NGM Biopharmaceuticals Inc., South San Francisco, Calif. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Endocrine/Metabolic, Hepatic The companies partnered to discover, develop and commercialize …

    Published on 3/2/2015
  • NPS, Shire deal

    NPS Pharmaceuticals Inc., Bedminster, N.J. Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Ophthalmic Shire completed its acquisition of NPS for $46 per share (see BioCentury, Jan. 19).

    Published on 3/2/2015
  • PanGenetics, Bioceros deal

    PanGenetics B.V., Utrecht, the Netherlands Bioceros B.V., Utrecht, the Netherlands Business: Cancer PanGenetics granted Bioceros exclusive, worldwide rights to develop preclinical mAb agonists of CD40 to treat cancer. …

    Published on 3/2/2015
  • Panoptes Pharma, Mediolanum Farmaceutici deal

    Panoptes Pharma GmbH, Vienna, Austria Mediolanum Farmaceutici S.p.A., Milan, Italy Business: Ophthalmic Panoptes granted Mediolanum rights to market PP-001 in two undisclosed European countries. Panoptes received an …

    Published on 3/2/2015
  • Plexpress, ValiRx deal

    Plexpress Oy, Helsinki, Finland ValiRx plc (LSE:VAL), London, U.K. Business: Cancer ValiRx acquired all Plexpress assets and IP, specifically its Transcript Analysis with the Aid of Affinity Capture (TRAC) gene …

    Published on 3/2/2015
  • QR Pharma, Rockefeller University deal

    QR Pharma Inc., Berwyn, Pa. Rockefeller University, New York, N.Y. Business: Neurology QR Pharma partnered with the university for preclinical testing of QRs Posiphen for Huntingtons disease. Rockefeller will use stem …

    Published on 3/2/2015
  • Rigel Pharmaceuticals Inc, Bristol-Myers deal

    Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Business: Cancer Rigel granted Bristol-Myers exclusive, worldwide rights to develop and …

    Published on 3/2/2015
  • Salix Pharmaceuticals Ltd, Valeant Pharmaceuticals deal

    Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec Business: Gastrointestinal Valeant will acquire Salix for $158 per share in cash, or …

    Published on 3/2/2015
  • Affinivax, PATH deal

    Affinivax Inc., Cambridge, Mass. PATH, Seattle, Wash. Business: Infectious Affinivax and PATH partnered to develop Affinivaxs vaccine candidate to prevent Streptococcus pneumoniae infections. The vaccine was developed …

    Published on 2/23/2015
  • Eagle Pharmaceuticals Inc, Teva deal

    Eagle Pharmaceuticals Inc. (NASDAQ:EGRX), Woodcliff Lake, N.J. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Cancer Eagle granted Teva exclusive, U.S. rights to commercialization EP-3102…

    Published on 2/23/2015
  • Genticel S.A, Serum Institute of India deal

    Genticel S.A. (Euronext:GTCL), Labege, France Serum Institute of India Ltd., Pune, India Business: Infectious Genticel granted the institute exclusive rights to Vaxiclase technology in acellular multivalent combination …

    Published on 2/23/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993